Clinical trial · Observational
Genomic Study of Relapse Esophageal Cancer After Radiotherapy
NCT04694391CI-TRIAL-00049644unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. However, about half patients received radiotherapy occurred relapse. Once relapse occurred, there is no better treatment strategy. Genomic study of relapsed esophageal cancer is seldom. So the investigators attempt to collect relapsed tissue to conduct with whole exome sequencing in order to investigate the genome landscape of recurrence esophageal cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gene Mutation-Related Cancer | Esophageal Neoplasm | PROBABILISTIC | 0.70 |
| Radiation Exposure | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| whole exome sequence | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Recurrence
- description
- The period of recurrence was within 2 years after radiotherapy. Pathologic diagnosis was squamous cell carcinoma same with preradiotherapy.
- interventionNames
- Genetic: whole exome sequence
- label
- No recurrence
- description
- The period was more than 3 years after radiotherapy and no recurrence signs were observed.
- interventionNames
- Genetic: whole exome sequence
Primary outcomes (1)
- measure
- genomic characteristics of relapsed esophageal cancer
- timeFrame
- through study completion, an average of 1 year
- description
- gene mutations, copy number variants
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. pathologic diagnosis is squamous cell carcinoma before radiotherapy; 2. pathologic diagnosis is squamous cell carcinoma after radiotherapy; 3. received radiotherapy 4. clinical symptoms including dysphagia, feeding obstruction, etc 5. image evidence showed disease progression 6. the period of recurrence was within 2 years after radiotherapy Exclusion Criteria: 1. pathologic diagnosis is not squamous cell carcinoma before radiotherapy; 2. pathologic diagnosis is not squamous cell carcinoma after radiotherapy 3. not received radiotherapy 4. the period of recurrence was more than 2 years after radiotherapy 5. the period of no recurrence was within 3 years after radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.